The Globe and Mail reports in its Friday edition that Desjardins Securities analyst Gary Ho continues to rate Dentalcorp Holdings "buy." The Globe's David Leeder writes in the Eye On Equities column that Mr. Ho, after previewing the release of Dentalcorp's fourth quarter 2023 results, bumped his share target to $11.50 from $11. Analysts on average target the shares at $9.93. Mr. Ho says in a note: "We expect 4Q revenue, SSSG and EBITDA/margin to be within guidance, and made small tweaks to our 2024/25 forecasts. The setup for the quarter looks favourable, and management's execution of its guidance should be viewed positively. We are hopeful that 2024 will have less noise, with margin expansion and decent FCF to self-fund acquisitions and help further deleverage." The Globe reported on Oct. 5 that Stifel analyst Justin Keywood had reaffirmed his "buy" call on Dentalcorp when it was worth $6.17. The Globe reported on Oct. 20 that Mr. Ho had reaffirmed his "buy" recommendation for Dentalcorp. The shares were then worth $5.91. The Globe reported on Jan. 5 that Scotia Capital analyst George Doumet rated Dentalcorp "sector outperform." He said he saw "significant upside" at Dentalcorp, which was then worth $7.08.